GlassScriptPhysician profile
Dexter W Walcott
NPI 1457321325
$153,748.78
in general payments reported to CMS, 2019-2025
36 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $13K · 2021: $19K · 2022: $20K · 2023: $23K · 2024: $25K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $8,420 · Travel and Lodging: $2,654 · Consulting Fee: $1,464 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,905.30 |
| Food and Beverage | $8,420.28 |
| Travel and Lodging | $2,654.09 |
| Consulting Fee | $1,464.00 |
| Education | $194.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $92,837.04 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $43,822.78 | 2019-2025 | Dupixent |
| Covis Pharma Gmbh | $5,278.54 | 2019 | |
| Glaxosmithkline, LLC. | $2,482.38 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,017.06 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $1,799.16 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Pfizer INC. | $852.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $613.21 | 2019-2025 | |
| Genentech USA, INC. | $608.32 | 2019-2025 | Xolair |
| Amgen INC. | $516.22 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $437.14 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Octapharma USA, INC. | $396.70 | 2023-2025 | Panzyga, Cutaquig, Octagam Immune Globulin (Human) |
| Leo Pharma INC. | $204.01 | 2022-2025 | Anzupgo, Adbry |
| Optinose US, INC. | $180.50 | 2019-2025 | |
| Pharming Healthcare, INC. | $177.36 | 2020-2025 | Ruconest |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $166.86 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $157.81 | 2021-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.51 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.88 | 2020-2024 | Takhzyro |
| Sanofi-Aventis U.S. LLC | $141.99 | 2019-2024 | |
| Kaleo, INC. | $129.20 | 2019-2023 | Auvi-Q |
| Abbvie INC. | $104.51 | 2022-2023 | Rinvoq |
| Blueprint Medicines Corporation | $86.09 | 2023-2024 | Ayvakit |
| Galderma Laboratories, L.P. | $72.26 | 2025 | Nemluvio |
| Shire North American Group INC | $51.66 | 2019 | |
| Lilly USA, LLC | $44.46 | 2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $44.26 | 2019-2023 | |
| Incyte Corporation | $41.12 | 2022-2023 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $36.67 | 2019-2021 | |
| Ionis Pharmaceuticals, INC. | $33.78 | 2025 | Dawnzera |
| Greer Laboratories, INC. | $23.47 | 2019 | |
| Dermavant Sciences, INC. | $22.55 | 2024 | Vtama |
| Gebauer Company | $20.12 | 2022 | |
| Mylan Specialty L.P. | $17.59 | 2020 | |
| Biocryst Pharmaceuticals, INC. | $13.35 | 2020 | |
| Organon LLC | $7.74 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dexter Walcott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.